News

Learn how and why East Indian Sandalwood Oil (EISO) is making international headlines as a unique, non-substitutable botanical drug candidate.

ViroXis Corporation Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize an OTC Dermatology Product

Posted on

February 26, 2014 06:00 AM Eastern Standard Time SAN ANTONIO–(MEDIA)–ViroXis Corporation is pleased to report the execution of an exclusive license agreement with a global pharmaceutical company for the marketing of an overthe-counter (OTC) sandalwood oil-containing product. The long-term agreement includes a licensing fee, milestone payments and royalties based on product sales. The pharmaceutical partner is exclusively dedicated to dermatology […]Read More ViroXis Corporation Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize an OTC Dermatology Product

Santalis Pharmaceuticals Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize OTC Dermatology Products

Posted on

February 26, 2014 06:00 AM Eastern Standard Time SAN ANTONIO–(MEDIA)–Santalis Pharmaceuticals Inc., a joint venture with TFS Corporation Ltd., of Australia (ASX: TFC) is pleased to report the execution of an exclusive license agreement with a global pharmaceutical company for the marketing of a number of over-the-counter (OTC) dermatology products containing TFS’ sustainably cultivated, pharmaceutical-grade East Indian Sandalwood Oil (EISO). […]Read More Santalis Pharmaceuticals Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize OTC Dermatology Products

ViroXis Corporation Achieves Key Clinical Milestones

Posted on

February 20, 2014 07:00 AM Eastern Standard Time SAN ANTONIO–(MEDIA)–ViroXis Corporation today announced that the final patient has completed treatment in its Phase 2 clinical study of the Company’s East Indian Sandalwood Oil (EISO) based therapy for HPV/common skin warts. Efficacy and safety results will be known once the data is analyzed in April following a three-month follow-up period. A total […]Read More ViroXis Corporation Achieves Key Clinical Milestones